Consensus Recursion Pharmaceuticals, Inc.

Stocks

RXRX

US75629V1044

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-01 EDT			5-day change	1st Jan Change
4.070 ^USD	-1.45%		+4.63%	-0.49%

09-21	Recursion Pharmaceuticals, Inc. Grants Tempus Ai, Inc. Non-Exclusive License for Rna Foundation Model	CI
09-21	Tempus AI, Recursion Extend Data License, Amend Fee Structure	MT

Evolution of the Average Target: Recursion Pharmaceuticals, Inc.

Evolution of the Target Price: Recursion Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Recursion Pharmaceuticals, Inc.

c639173171003b33.ryLo3lMR7xoyP0E46v6kTo5UE2zDv-bnYOj9QpA4HP4.xHWbmWd5oHdFWg9IvJbmO-Jmagmch7alVI3LNKRpW5jVbZiRFyDfX3h0cQ~1dcd84e9bddff548e7ac20f47d6e4795

Analysts' recommendations: Recursion Pharmaceuticals, Inc.

08-17	Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says	MT
08-17	Morgan Stanley Adjusts PT on Recursion Pharmaceuticals to $5.30 From $5.50, Keeps Equalweight Rating	MT
05-14	Morgan Stanley Raises Price Target on Recursion Pharmaceuticals to $5.50 From $5, Keeps Equalweight Rating	MT
12-17	Recursion Pharmaceuticals Shares Rise After JPMorgan Upgrade	MT
12-17	Recursion Pharmaceuticals rises 13.1% after JP Morgan raises co to 'overweight' from 'neutral'	RE
12-17	JPMorgan Upgrades Recursion Pharmaceuticals to Overweight From Neutral, Adjusts PT to $11 From $10	MT
11-17	Centessa Pharmaceuticals, CG Oncology Drive Q3 Biotech Momentum, Morgan Stanley Says	MT
11-17	Morgan Stanley Raises Price Target on Recursion Pharmaceuticals to $5 From $4.80, Keeps Equalweight Rating	MT
11-05	Recursion Pharmaceuticals, Inc. Announces Management Changes, Effective January 1, 2026	CI
25-08-05	Biotech firm Recursion's Q2 revenue beats estimates	RE
25-06-16	Morgan Stanley Cuts Recursion Pharmaceuticals Price Target to $5 From $8, Maintains Equalweight Rating	MT
25-01-08	KeyBanc Lowers Price Target on Recursion Pharmaceuticals to $10 From $12, Keeps Overweight Rating	MT
25-01-07	BofA Securities Cuts Price Target on Recursion Pharmaceuticals to $10 From $12, Maintains Neutral Rating	MT
24-09-03	Jefferies Cuts Price Target on Recursion Pharmaceuticals to $6 From $8, Maintains Hold Rating	MT
24-07-11	KeyBanc Cuts Price Target on Recursion Pharmaceuticals to $12 From $16, Maintains Overweight Rating	MT
24-07-09	Jefferies Initiates Recursion Pharmaceuticals at Hold With $8 Price Target	MT
24-02-28	Needham Raises Price Target on Recursion Pharmaceuticals to $17 From $15, Maintains Buy Rating	MT
24-01-26	TD Cowen Starts Recursion Pharmaceuticals With Market Perform Rating	MT
23-11-13	JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating	MT
23-11-10	Needham Adjusts Recursion Pharmaceuticals Price Target to $15 From $17, Maintains Buy Rating	MT
23-07-13	KeyBanc Adjusts Price Target on Recursion Pharmaceuticals to $15 From $12, Maintains Overweight Rating	MT
23-07-13	Berenberg Bank Adjusts Recursion Pharmaceuticals Price Target to $35 From $33, Maintains Buy Rating	MT
23-07-13	Morgan Stanley Lifts Price Target on Recursion Pharmaceuticals to $11 From $8 Amid NVIDIA Partnership, Keeps Equalweight Rating	MT
23-05-09	Keybanc Adjusts Price Target on Recursion Pharmaceuticals to $12 From $20, Keeps Overweight Rating	MT
23-03-16	Needham Starts Recursion Pharmaceuticals at Buy With $17 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	RECURSION PHARMACEUTICALS, INC.					+77.31%
	WUXI APPTEC CO., LTD.					+11.79%
	ARGENX SE					+23.73%
	LONZA GROUP AG					+22.76%
	IQVIA HOLDINGS INC.					+10.75%
	REVOLUTION MEDICINES, INC.					+25.05%
	BEONE MEDICINES AG					+20.83%
	CELLTRION, INC.					+45.83%
	WUXI BIOLOGICS (CAYMAN) INC.					+3.91%
	INSMED INCORPORATED					+82.1%
	Average					+32.41%
	Weighted average by Cap.					+23.85%